mechanism of action of glp-1 receptor agonists Frontiers GLP-1RAs Reduce External Eating Behavior

Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases

CD, n=258) who were prescribed a GLP1RA (liraglutide, semaglutide, tirzepatide) at least twice, identified on the Mayo Clinic Platform, included in this study, and matched with controls with IBD but not treated with GLP1RA

One study compared them directly and found that gastric emptying half-time was delayed by 52 minutes with lixisenatide (short-acting) but only 25 minutes with liraglutide (long-acting) [2]

A higher dose of liraglutide, up to 3 mg daily (Saxenda), has been approved by the US FDA for weight management in certain obese or overweight individuals

Despite fasting from solid food for more than 18 hours prior to evaluation, she described feeling full. A point-of-care gastric ultrasound was performed, which revealed solid gastric contents

[DOI] [PubMed] [Google Scholar] 208.Williams L.T., Barnes K., Ball L., Ross L.J., Sladdin I., Mitchell L.J